Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Exclusion Criteria

• •Concomitant diagnosis of another form of chronic, recurrent angioedema, such as acquired angioedema, idiopathic angioedema, or recurrent angioedema associated with urticaria.
• •Participation in a prior DX-2930 study
• •Treatment with any other investigational drug or exposure to an investigational device within 4 weeks prior screening
• •Exposure to angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications within 4 weeks prior to screening.
• •Exposure to androgens within 2 weeks prior to entering the run-in period.
• •Use of long-term prophylactic therapy for HAE within 2 weeks prior to entering the run-in period.
• •Use of short-term prophylaxis for HAE within 7 days prior to entering the run-in period.
• •Any of the following liver function test abnormalities: alanine aminotransferase (ALT) \> 3x upper limit of normal, or aspartate aminotransferase (AST) \> 3x upper limit of normal, or total bilirubin \> 2x upper limit of normal (unless the bilirubin elevation is a result of Gilbert's syndrome).
• •Pregnancy or breastfeeding.